![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.220.474 ![]() |
Chemical and physical data | |
Formula | C18H23NO3S |
Molar mass | 333.45 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.[1][2][3][4]
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.[2]
Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.[5] Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an EC50 of 3.0 μM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model.[6] Inhibits HUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.[7]
PPARαTooltip Peroxisome proliferator-activated receptor alpha |
|
---|---|
PPARδTooltip Peroxisome proliferator-activated receptor delta |
|
PPARγTooltip Peroxisome proliferator-activated receptor gamma |
|
Non-selective | |
|
CARTooltip Constitutive androstane receptor |
|
---|---|
PXRTooltip Pregnane X receptor |
|
|